Product Description
Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Nuplazid cases. Here at Leading Justice, we can customize your firm’s Nuplazid advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Nuplazid advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We will also cross-qualify all of our contacts, which means any data we generate that doesn’t qualify for the target campaign will be reviewed to determine whether it is eligible for another type of claim. By using innovative approaches to target contacts specifically related to Nuplazid use and side effects like worsened hallucinations and delusions or wrongful death, Leading Justice will increase your firm’s Nuplazid caseload. If you are interested in helping victims of alleged Nuplazid side effects, our extensive consumer reach and direct advertising strategies give you the competitive edge and confidence you need to allocate your full budget, knowing your money is being used in the best way possible.
Each and every law firm we work with at Leading Justice plays a critical role in determining how we classify claims as qualified or not. While our experience working with plaintiff law firms helps us recognize a great case when we see one, we will custom tailor our Nuplazid case intake specifications to the exact criteria you are seeking. So, if your firm has specific Nuplazid qualifying case criteria you would like us to use, we will train our intake specialists to apply the criteria to each phone call and email they receive. By eliminating the middle man, Leading Justice offers clients an opportunity for internal cash buys of Nuplazid data with zero chance of fraud.
Nuplazid Side Effect Litigation
Nuplazid (pimavanserin) is a new-generation antipsychotic medication manufactured by Acadia Pharmaceuticals and marketed as a landmark treatment for psychosis symptoms in patients with Parkinson’s disease. Nuplazid’s approval in April 2016 was fast-tracked by the FDA because the drug was considered a “breakthrough therapy” for patients suffering from Parkinson’s-related psychosis. It was claimed at the time that Nuplazid demonstrated a “substantial improvement” over other available treatments for Parkinson’s patients, and could help lessen the symptoms of psychosis that often occur with the advanced stages of the disease, like hallucinations and delusions. However, within two years of Nuplazid’s approval, reports began to surface of Parkinson’s patients on Nuplazid experiencing worsened hallucinations and other adverse effects, and the medication has since been linked to more than 700 patient deaths.
It was in November 2017, just 19 months after Nuplazid was first approved, that the Institute for Safe Medication Practices (ISMP) published its QuarterWatch report tying Nuplazid treatment to as many as 244 patient deaths occurring during the drug’s first year on the market. According to the ISMP report, Nuplazid’s approval was based on a single clinical trial of only 200 patients taking the antipsychotic medication, and that trial followed three previous studies that failed to demonstrate any benefit at all with Nuplazid treatment. In the months following the ISMP report, the FDA identified as many as 1,860 reports of serious adverse events connected to Nuplazid therapy in Parkinson’s patients, including as many as 712 deaths. As a result of this alarming drug risk profile, the FDA reported in April 2018 that it would be re-examining the safety of Nuplazid treatment among patients experiencing Parkinson’s disease-related psychosis. In the meantime, wrongful death claims are expected to be filed by families across the country who believed Nuplazid would give their loved ones a reprieve from Parkinson’s-related psychosis, delusions and hallucinations.
